Largest Presence Ever for STAAR Surgical and the Visian® ICL Technology at Upcoming ESCRS
"STAAR's presence at the ESCRS increases each year and this will be another exciting and productive week in our history," said Hans Blickensdoerfer, President of
STAAR is hosting its 11th Annual Visian ICL Experts Meeting in
- Dr. Zaldivar from
Argentina will look back on his 20 years of experience with the Visian ICL technology and how the enhancements to the product have provided increased efficacy and safety over those years. - Benefits of the new Visian ICL Preloaded System which gained CE Mark approval in late June will be discussed.
- Technical presentation of the visual simulation of the new ICL optic design, for which a Provisional Patent Application has been filed. This optic is designed to delay the need for reading glasses in those over the age of 40.
- Dr. Alfonso from
Spain will present his clinical data reflecting the enhanced safety profile of the Visian ICL with CentraFLOW after three years of successful implants. - Dr. Kwon from
Korea will present how same day ICL procedures have impacted patient and surgeon experience. - Dr. Eissa from
Saudi Arabia will present why he chose the Visian ICL for his own eyes.
A lunch symposium during the ESCRS meeting will take place on Saturday. The title of the Symposium is Refractive Surgery and Preserving the Cornea for the Future. Key speakers and presentations will be made by: Dr.
New product highlights will include the marketing launch of the preloaded ICL system, which gained CE Mark approval in June. The week will also feature initial technical presentations on the optic results from the V6a ICL project for which a confirmatory study is set to begin at the end of this month. The V6a ICL differentiates ICL for myopic patients nearing age 40 who will need near and intermediate adds.
About
STAAR, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems therefor. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or "ICL." A lens used to replace the natural lens after cataract surgery is called an intraocular lens or "IOL." More than 450,000 Visian ICLs have been implanted to date; to learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 335 full time employees and markets lenses in over 60 countries. Headquartered in
Safe Harbor
All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: objectives of management for future operations or prospects for achieving its plans; statements regarding new or improved products, including but not limited to, expectations for success of new or improved products in the U.S. or international markets or government approval of new or improved products; future economic conditions or size of market opportunities; expected costs and savings from business consolidation plans and the timetable for those plans; statements of belief, including as to achieving 2014 growth plans or metrics; expected regulatory activities and approvals, product launches, and any statements of assumptions underlying any of the foregoing. Important additional factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's Annual Report on Form 10-K for the year ended
These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: our limited capital resources and limited access to financing; the negative effect of unstable global economic conditions on sales of products, especially products such as the ICL used in non-reimbursed elective procedures; the challenge of managing our foreign subsidiaries; backlog or supply delays as we fully integrate our manufacturing facility consolidation; the risk of unfavorable changes in currency exchange rate; the discretion of regulatory agencies to approve or reject new or improved products, or to require additional actions before approval (including but not limited to
CONTACT: |
Investors |
Media |
EVC Group |
EVC Group |
|
Doug Sherk |
Nicole Kruse |
|
415-652-9100 |
212-850-6025 |
SOURCE